Newomics is dedicated to creating and commercializing innovative (New) and integrative (Omics) platforms and solutions for precision medicine. The company's products deliver the robustness of microflow LC and the sensitivity of nanospray ionization MS. The plug-and-play MnESI platform (MnESI source + M3 emitter) is currently interfaced to diverse MS instruments and can be ordered at www.newomics.com.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/01/20 | $7,900,000 | Series B |
Berkeley Catalyst Fund LDV Partners MSA Capital  Photon Fund | undisclosed |
